Covid vaccine latest: AstraZeneca now linked to 'transverse myelitis' - MHRA warning
ASTRAZENECA, now referred to as Vaxzevria by the Medicines and Healthcare Regulatory Agency (MHRA), has been associated with cases of transverse myelitis - i.e. inflammation of the spinal cord.
"Treatment for transverse myelitis includes medications and rehabilitative therapy," the Mayo Clinic noted.
While "most people" are expected to recover, "at least partially", those with severe attacks may be left with "major disabilities".
The symptoms of transverse myelitis may develop within a few hours to several weeks.
Pain might begin suddenly in the lower back, with shooting pain travelling down the legs, arms, chest or abdomen.
ASTRAZENECA, now referred to as Vaxzevria by the Medicines and Healthcare Regulatory Agency (MHRA), has been associated with cases of transverse myelitis - i.e. inflammation of the spinal cord.
"Treatment for transverse myelitis includes medications and rehabilitative therapy," the Mayo Clinic noted.
While "most people" are expected to recover, "at least partially", those with severe attacks may be left with "major disabilities".
The symptoms of transverse myelitis may develop within a few hours to several weeks.
Pain might begin suddenly in the lower back, with shooting pain travelling down the legs, arms, chest or abdomen.
Comment